As a full non-BA agonist of FXR, GW4064, notable for its high potency and selectivity, significantly decreases serum cholesterol and triglyceride levels in individuals with NAFLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.